Compare ENR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | IOVA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2015 | 2008 |
| Metric | ENR | IOVA |
|---|---|---|
| Price | $20.25 | $4.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $23.14 | $9.00 |
| AVG Volume (30 Days) | 1.0M | ★ 12.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.48% | N/A |
| EPS Growth | ★ 538.46 | 14.84 |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $3.87 | $47.74 |
| Revenue Next Year | $0.85 | $40.31 |
| P/E Ratio | $5.99 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $15.75 | $1.67 |
| 52 Week High | $30.29 | $5.63 |
| Indicator | ENR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 53.47 |
| Support Level | $19.37 | $2.07 |
| Resistance Level | $20.94 | $4.35 |
| Average True Range (ATR) | 0.64 | 0.36 |
| MACD | 0.23 | -0.02 |
| Stochastic Oscillator | 81.85 | 40.45 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.